105 related articles for article (PubMed ID: 26574635)
1. Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.
Li Y; Zhang J
Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):110-116. PubMed ID: 26574635
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
3. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
4. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
5. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
6. The expression profile and prognostic value of APE/Ref-1 and NPM1 in high-grade serous ovarian adenocarcinoma.
Fan X; Wen L; Li Y; Lou L; Liu W; Zhang J
APMIS; 2017 Oct; 125(10):857-862. PubMed ID: 28766835
[TBL] [Abstract][Full Text] [Related]
7. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
9. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
11. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
12. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.
Bignotti E; Todeschini P; Calza S; Falchetti M; Ravanini M; Tassi RA; Ravaggi A; Bandiera E; Romani C; Zanotti L; Tognon G; Odicino FE; Facchetti F; Pecorelli S; Santin AD
Eur J Cancer; 2010 Mar; 46(5):944-53. PubMed ID: 20060709
[TBL] [Abstract][Full Text] [Related]
13. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
15. Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma.
Chen L; Liu X; Zhang J; Liu Y; Gao A; Xu Y; Lin Y; Du Q; Zhu Z; Hu Y; Liu Y
Int J Clin Exp Pathol; 2018; 11(10):4977-4986. PubMed ID: 31949574
[TBL] [Abstract][Full Text] [Related]
16. [Activation of JAK/STAT in ovarian high-grade serous cancers and its prognostic significance].
Yang J; DU J; Wang YX; Liu CR
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):270-275. PubMed ID: 37042137
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Dos Santos MV; Holth A; Lindemann K; Staff AC; Davidson B
Gynecol Oncol; 2023 Sep; 176():76-81. PubMed ID: 37478615
[TBL] [Abstract][Full Text] [Related]
18. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas.
Gilks CB; Irving J; Köbel M; Lee C; Singh N; Wilkinson N; McCluggage WG
Am J Surg Pathol; 2015 Mar; 39(3):357-64. PubMed ID: 25517954
[TBL] [Abstract][Full Text] [Related]
19. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
20. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.
Quinn MC; Wojnarowicz PM; Pickett A; Provencher DM; Mes-Masson AM; Davis EC; Tonin PN
Int J Oncol; 2013 Mar; 42(3):912-20. PubMed ID: 23354471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]